Professor of Medicine
William J. Koopman Endowed Professor in Rheumatology and Immunology
Director, UAB Arthritis Clinical Intervention Program
Co-Director, UAB Center for Education and Research on Therapeutics (CERTS) of Musculoskeletal Disorders
Co-Director, UAB PharmacoEpidEmiology and phaRmcoeconomics (PEER) Unit
Faculty Offices Tower, room 802
510 20th Street South
Birmingham, AL 35294
BS (Biology), University of California at San Diego
MD, Oregon Health & Sciences University, Portland, OR
MPH, Oregon Health & Sciences University, Portland, OR
Residency (Internal Medicine): Oregon Health & Science University
Fellowship (Clinical Immunology and Rheumatology): University of Alabama at Birmingham
MS (Epidemiology), Harvard School of Public Health
Postdoctoral (Clinical Informatics): Stanford University
Research and Clinical Interests
Dr. Curtis is the Co-Director of the UAB Center for Education and Research on Therapeutics (CERTs) of Musculoskeletal Disorders, which has a major emphasis on evaluating the safety and comparative effectiveness of medications for rheumatic diseases. Additionally, as the Director of the UAB Arthritis Clinical Intervention Program, he leads the clinical trials unit for the rheumatology division at UAB, with a particular focus on rheumatoid arthritis (RA) and psoriatic arthritis (PsA). He is the Co-Director of the UAB Pharmacoepidemiology and Pharmacoeconomics Research (PEER) Unit. PEER uses multiple large data sources to study comparative effectiveness questions across multiple chronic diseases. These data sources include national administrative data from Medicare and commercial health plans, electronic health record data, and large registries. He has been awarded the William J. Koopman Endowed Professorship in Rheumatology and Immunology.
The evaluation of the efficacy, comparative effectiveness, and safety of the medications used to treat rheumatoid arthritis and spondyloarthritis are among Dr. Curtis’s research interests. He served on the Core Expert Panel for the ACR’s 2008 and 2012 Recommendations for the Use of Nonbiologic and Biologic Disease Modifying Antirheumatic Drugs in RA and is part of the forthcoming 2015 ACR Recommendations. He was the Deputy Director for a collaborative project between the FDA, the Agency for Healthcare Research and Quality (AHRQ), and a number of academic centers studying the safety of biologic agents using multiple, pooled national data sources. He is the Co-PI of the PCORI-funded Patient Powered Research Network “Arthritis-Power” registry, focused on RA, psoriasis, and psoriatic arthritis. He also leads the multi-center NIH-funded large pragmatic randomized controlled trial studying the safety and effectiveness of the live herpes zoster vaccine in patients receiving biologic agents.
Dr. Curtis also studies risk factors for and outcomes of osteoporosis. He was a member of the ACR’s task force to update recommendations for the management of glucocorticoid induced osteoporosis (GIOP). He also served on the ASBMR Task Force on Atypical Subtrochanteric and Diaphyseal Fractures.
Dr. Curtis is a member of the American College of Rheumatology (ACR), the International Society for Pharmacoepidemiology (ISPE), and the American Society of Bone and Mineral Research (ASBMR). He has been on the editorial board for Arthritis & Rheumatism, Pharmacoepidemiology and Drug Safety (PDS) and Arthritis Care and Research (AC&R). He has authored more than 250 original peer-reviewed manuscripts.
Click here for a complete list of publications. Below are a few selected papers.
Herrinton LJ, Harrold LR, Liu L, Raebel MA, Taharka A, Winthrop KL, Solomon DH, Curtis JR, Lewis JD, Saag KG. 2013. Association between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf. 2013 Jan 29. PMID: 23359391
Dewitt EM, Li Y, Curtis JR, Glick HA, Greenberg JD, Anstrom KJ, Kremer JM, Reed G, Schulman KA, Reed SD. 2013. Comparative Effectiveness of Nonbiologic versus Biologic Disease-modifying Antirheumatic Drugs for Rheumatoid Arthritis. J Rheumatol. 40(2):127-136. PMID: 23322461
Yazici Y, Curtis JR, Ince A, Baraf HS, Lepley DM, Devenport JN, Kavanaugh A. 2013. Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a 1-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study). Clin Exp Rheumatol. 2013 Jan 10. [Epub ahead of print] PMID: 23305631
Solomon DH, Rassen JA, Kuriya B, Chen L, Harrold LR, Graham DJ, Lewis JD, Lii J, Liu L, Griffin MR, Curtis JR. 2012. Heart failure risk among patients with rheumatoid arthritis starting a TNF antagonist. Ann Rheum Dis. 2012 Nov 15. PMID: 23155221
Herrinton LJ, Liu L, Chen L, Harrold LR, Raebel MA, Curtis JR, Griffin MR, Solomon DH, Saag KG, Lewis JD. 2012. Association between anti-TNF-α therapy and all-cause mortality. Pharmacoepidemiol Drug Saf. 21(12):1311-20. PMID: 23065964
Haynes K, Beukelman T, Curtis JR, Newcomb C, Herrinton LJ, Graham DJ, Solomon DH, Griffin MR, Chen L, Liu L, Saag KG, Lewis JD; SABER Collaboration. 2013. Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum. 65(1):48-58. PMID: 23055441
Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, Fernandes J, McMahan RM, Baddley JW, Saag KG, Beukelman T, Delzell E. 2012. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 64(10):1480-9. PMID: 22833479
Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. 2012. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 308(1):43-9. PMID: 22760290
Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y, Ramanujan S, Cavet G, Centola M, Hesterberg LK, Chernoff D, Ford K, Shadick NA, Hamburger M, Fleischmann R, Keystone E, Weinblatt ME. 2012. Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken). 64(12):1794-803. PMID: 22736476
Curtis JR, Lanas A, John A, Johnson DA, Schulman KL. 2012. Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 64(12):1819-28. PMID: 22730417
Curtis JR, Yun H, Lange JL, Matthews R, Sharma P, Saag KG, Delzell E. 2012. Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data. Arthritis Care Res (Hoboken). 64(12):1855-63. PMID: 22730364
Curtis JR, Sharma P, Arora T, Bharat A, Barnes I, Morrisey MA, Kilgore M, Saag KG, Wright NC, Yun HG, Delzell E. 2013. Physicians' explanations for apparent gaps in the quality of rheumatology care: Results from the US Medicare Physician Quality Reporting System. Arthritis Care Res (Hoboken). 65(2):235-43. PMID: 22556118